JNJ
Johnson & Johnson
Price Chart
Latest Quote
$232.75
+4.58 (+2.01%)
Current Price
| Previous Close | $228.17 |
| Open | $230.00 |
| Day High | $235.21 |
| Day Low | $229.00 |
| Volume | 4,728,036 |
Stock Information
| Quarterly Dividend / Yield | $5.36 / 2.35% |
| Shares Outstanding | 2.41B |
| Quarterly Dividend Yield | 2.35% |
| Quarterly Dividend | $5.36 |
| Total Debt | $54.99B |
| Cash Equivalents | $22.05B |
| Revenue | $96.36B |
| Net Income | $21.04B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $560.33B |
| P/E Ratio | 27.00 |
| EPS (TTM) | $8.62 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $582.19B |
| Sales | $96.36B |
| Income | $21.04B |
| Book/sh | $33.73 |
| Cash/sh | $9.16 |
| Employees | 138K |
Financial Ratios
| Quick Ratio | 0.69 |
| Current Ratio | 1.02 |
| Debt/Eq | 67.73 |
| EPS Growth TTM | -52.40% |
Returns & Margins
| ROA | 8.42% |
| ROE | 26.42% |
| Gross Margin | 68.04% |
| Operating Margin | 27.41% |
| Profit Margin | 21.83% |
Ownership
| Insider Ownership | 0.05% |
| Institutional Ownership | 76.83% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 18.30 |
| PEG | 2.90 |
| P/S | 5.81 |
| P/B | 6.90 |
Analyst Data
| Recommendation | buy |
| Target Price | $252.87 |
Technical Indicators
| SMA20 | $227.15 |
| SMA50 | $230.36 |
| SMA200 | $210.87 |
| RSI | 61.81 |
| ATR | 4.2131 |
| Shares Float | 2.40B |
| Short Float | 1.07% |
| Short Ratio | 2.96 |
| Volatility | 0.26 |
| Rel Volume | 0.74 |
Performance History
| Week | +3.30% |
| Month | +4.22% |
| Quarter | -2.62% |
| 6 Months | +14.62% |
| YTD | +13.51% |
| Year | +55.71% |
| 3 Years | +63.85% |
| 5 Years | +58.30% |
| 10 Years | +164.35% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $232.77 | 5,636,649 |
| 2026-06-04 | $228.17 | 7,274,800 |
| 2026-06-03 | $223.24 | 6,507,200 |
| 2026-06-02 | $222.89 | 5,669,000 |
| 2026-06-01 | $223.51 | 8,041,000 |
| 2026-05-29 | $225.33 | 13,897,700 |
| 2026-05-28 | $230.80 | 7,193,400 |
| 2026-05-27 | $231.29 | 5,835,500 |
| 2026-05-26 | $230.18 | 6,619,600 |
| 2026-05-22 | $233.00 | 5,462,300 |
| 2026-05-21 | $230.40 | 5,239,000 |
| 2026-05-20 | $228.01 | 7,353,800 |
| 2026-05-19 | $228.68 | 9,677,900 |
| 2026-05-18 | $227.61 | 10,141,600 |
| 2026-05-15 | $225.41 | 12,167,000 |
| 2026-05-14 | $229.48 | 6,974,400 |
| 2026-05-13 | $229.10 | 7,464,500 |
| 2026-05-12 | $222.98 | 8,632,500 |
| 2026-05-11 | $220.16 | 6,223,200 |
| 2026-05-08 | $220.05 | 5,550,600 |
| 2026-05-07 | $221.24 | 7,269,700 |
| 2026-05-06 | $223.34 | 7,982,300 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
đ° Latest News
Nasdaq plunges 1,100 points over renewed rate hike concerns
Yahoo Finance Video âĸ 2026-06-05T20:11:37Z
Why Laser Photonics (LASE) Is Up 288.5% After Nasdaq Noncompliance Notice Amid Defense Contract Momentum
Simply Wall St. âĸ 2026-06-05T20:05:19Z
J&J, Medtronic back CereVascâs $85M funding round
MedTech Dive âĸ 2026-06-05T16:48:00Z
Jim Cramer Says He Likes âKimberly-Clark Because Itâs Merging With Kenvueâ
Insider Monkey âĸ 2026-06-05T14:14:24Z
Jim Cramer Highlights Johnson & Johnson Having No Big Patent Expirations
Insider Monkey âĸ 2026-06-05T14:14:23Z
Five Boring Dividend Aristocrats That Quietly Pay $36,000 a Year on $850,000 Without a Single Yield Trap
24/7 Wall St. âĸ 2026-06-05T13:18:03Z
Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
Zacks âĸ 2026-06-05T13:07:00Z
Dividend Aristocrats on Sale: 5 Decades-Long Raisers Trading Below Target
24/7 Wall St. âĸ 2026-06-05T12:19:07Z
Best Consumer Dividend Stocks to Buy Now: HAS, KVUE, MOV
Zacks âĸ 2026-06-04T23:23:00Z
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
Zacks âĸ 2026-06-04T21:45:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $30,256,000,000 | $27,471,000,000 | $26,553,000,000 | $24,596,000,000 |
| Cost Of Revenue | $30,256,000,000 | $27,471,000,000 | $26,553,000,000 | $24,596,000,000 |
| Total Revenue | $94,193,000,000 | $88,821,000,000 | $85,159,000,000 | $79,990,000,000 |
| Operating Revenue | $94,193,000,000 | $88,821,000,000 | $85,159,000,000 | $79,990,000,000 |
| Expenses | ||||
| Interest Expense | $971,000,000 | $755,000,000 | $772,000,000 | $276,000,000 |
| Total Expenses | $68,597,000,000 | $67,572,000,000 | $63,150,000,000 | $58,977,000,000 |
| Other Income Expense | $6,891,000,000 | $-5,145,000,000 | $-7,436,000,000 | $-1,868,000,000 |
| Other Non Operating Income Expenses | $1,000,000,000 | $1,900,000,000 | $-6,634,000,000 | $-810,000,000 |
| Net Non Operating Interest Income Expense | $85,000,000 | $577,000,000 | $489,000,000 | $214,000,000 |
| Interest Expense Non Operating | $971,000,000 | $755,000,000 | $772,000,000 | $276,000,000 |
| Operating Expense | $38,341,000,000 | $40,101,000,000 | $36,597,000,000 | $34,381,000,000 |
| General And Administrative Expense | - | $22,869,000,000 | $21,512,000,000 | $20,246,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $26,804,000,000 | $14,066,000,000 | $13,326,000,000 | $16,370,000,000 |
| Net Interest Income | $85,000,000 | $577,000,000 | $489,000,000 | $214,000,000 |
| Interest Income | $1,056,000,000 | $1,332,000,000 | $1,261,000,000 | $490,000,000 |
| Normalized Income | $21,957,544,581 | $20,004,453,287 | $14,035,770,000 | $17,265,068,000 |
| Net Income From Continuing And Discontinued Operation | $26,804,000,000 | $14,066,000,000 | $35,153,000,000 | $17,941,000,000 |
| Net Income Common Stockholders | $26,804,000,000 | $14,066,000,000 | $35,153,000,000 | $17,941,000,000 |
| Net Income | $26,804,000,000 | $14,066,000,000 | $35,153,000,000 | $17,941,000,000 |
| Net Income Including Noncontrolling Interests | $26,804,000,000 | $14,066,000,000 | $35,153,000,000 | $17,941,000,000 |
| Net Income Discontinuous Operations | $0 | $0 | $21,827,000,000 | $1,571,000,000 |
| Net Income Continuous Operations | $26,804,000,000 | $14,066,000,000 | $13,326,000,000 | $16,370,000,000 |
| Pretax Income | $32,581,000,000 | $16,687,000,000 | $15,062,000,000 | $19,359,000,000 |
| Special Income Charges | $5,491,000,000 | $-6,745,000,000 | $-802,000,000 | $-1,058,000,000 |
| Interest Income Non Operating | $1,056,000,000 | $1,332,000,000 | $1,261,000,000 | $490,000,000 |
| Operating Income | $25,596,000,000 | $21,249,000,000 | $22,009,000,000 | $21,013,000,000 |
| Gross Profit | $63,937,000,000 | $61,350,000,000 | $58,606,000,000 | $55,394,000,000 |
| Per Share | ||||
| Diluted EPS | $11.03 | $5.79 | $13.72 | $6.73 |
| Basic EPS | $11.13 | $5.84 | $14.60 | $6.86 |
| Other | ||||
| Tax Effect Of Unusual Items | $1,044,544,581 | $-1,106,546,713 | $-92,230,000 | $-162,932,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $35,164,000,000 | $31,826,000,000 | $24,122,000,000 | $27,663,000,000 |
| Total Unusual Items | $5,891,000,000 | $-7,045,000,000 | $-802,000,000 | $-1,058,000,000 |
| Total Unusual Items Excluding Goodwill | $5,891,000,000 | $-7,045,000,000 | $-802,000,000 | $-1,058,000,000 |
| Reconciled Depreciation | $7,503,000,000 | $7,339,000,000 | $7,486,000,000 | $6,970,000,000 |
| EBITDA (Bullshit earnings) | $41,055,000,000 | $24,781,000,000 | $23,320,000,000 | $26,605,000,000 |
| EBIT | $33,552,000,000 | $17,442,000,000 | $15,834,000,000 | $19,635,000,000 |
| Diluted Average Shares | $2,429,400,000 | $2,429,400,000 | $2,560,400,000 | $2,663,900,000 |
| Basic Average Shares | $2,407,939,000 | $2,406,922,000 | $2,407,078,000 | $2,613,597,000 |
| Diluted NI Availto Com Stockholders | $26,804,000,000 | $14,066,000,000 | $35,153,000,000 | $17,941,000,000 |
| Tax Provision | $5,777,000,000 | $2,621,000,000 | $1,736,000,000 | $2,989,000,000 |
| Other Special Charges | $-6,000,000,000 | $5,500,000,000 | $7,300,000,000 | $2,600,000,000 |
| Impairment Of Capital Assets | $81,000,000 | $211,000,000 | $313,000,000 | $783,000,000 |
| Restructuring And Mergern Acquisition | $428,000,000 | $1,034,000,000 | $489,000,000 | $275,000,000 |
| Gain On Sale Of Security | $400,000,000 | $-300,000,000 | $-600,000,000 | $-700,000,000 |
| Research And Development | $14,665,000,000 | $17,232,000,000 | $15,085,000,000 | $14,135,000,000 |
| Selling General And Administration | $23,676,000,000 | $22,869,000,000 | $21,512,000,000 | $20,246,000,000 |
| Other Gand A | - | $22,869,000,000 | $21,512,000,000 | $20,246,000,000 |
| Salaries And Wages | - | $-900,000,000 | $-1,400,000,000 | $-1,200,000,000 |
Fetched: 2026-05-12
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-17,631,000,000 | $-10,328,000,000 | $-1,959,000,000 | $2,268,000,000 |
| Total Assets | $199,210,000,000 | $180,104,000,000 | $167,558,000,000 | $187,378,000,000 |
| Total Non Current Assets | $143,586,000,000 | $124,211,000,000 | $114,063,000,000 | $132,084,000,000 |
| Other Non Current Assets | $14,368,000,000 | $11,414,000,000 | $14,153,000,000 | $30,619,000,000 |
| Non Current Deferred Assets | $6,874,000,000 | $10,461,000,000 | $9,279,000,000 | $8,947,000,000 |
| Non Current Deferred Taxes Assets | $6,874,000,000 | $10,461,000,000 | $9,279,000,000 | $8,947,000,000 |
| Goodwill And Other Intangible Assets | $99,175,000,000 | $81,818,000,000 | $70,733,000,000 | $74,536,000,000 |
| Other Intangible Assets | $50,403,000,000 | $37,618,000,000 | $34,175,000,000 | $38,489,000,000 |
| Current Assets | $55,624,000,000 | $55,893,000,000 | $53,495,000,000 | $55,294,000,000 |
| Inventory | $14,191,000,000 | $12,444,000,000 | $11,181,000,000 | $10,268,000,000 |
| Receivables | $21,331,000,000 | $18,927,000,000 | $19,387,000,000 | $16,915,000,000 |
| Other Receivables | $4,153,000,000 | $4,085,000,000 | $4,514,000,000 | $2,876,000,000 |
| Accounts Receivable | $17,178,000,000 | $14,842,000,000 | $14,873,000,000 | $14,039,000,000 |
| Allowance For Doubtful Accounts Receivable | $-183,000,000 | $-167,000,000 | $-166,000,000 | $-169,000,000 |
| Gross Accounts Receivable | $17,361,000,000 | $15,009,000,000 | $15,039,000,000 | $14,208,000,000 |
| Cash Cash Equivalents And Short Term Investments | $20,102,000,000 | $24,522,000,000 | $22,927,000,000 | $22,281,000,000 |
| Cash And Cash Equivalents | $19,709,000,000 | $24,105,000,000 | $21,859,000,000 | $12,889,000,000 |
| Cash Equivalents | $16,410,000,000 | $21,187,000,000 | $18,519,000,000 | $9,198,000,000 |
| Cash Financial | $3,299,000,000 | $2,918,000,000 | $3,340,000,000 | $3,691,000,000 |
| Assets Held For Sale Current | - | - | $0 | $5,830,000,000 |
| Other Current Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $28,224,000,000 | $12,529,000,000 | $7,473,000,000 | $26,753,000,000 |
| Total Debt | $47,933,000,000 | $36,634,000,000 | $29,332,000,000 | $39,642,000,000 |
| Long Term Debt And Capital Lease Obligation | $39,438,000,000 | $30,651,000,000 | $25,881,000,000 | $26,886,000,000 |
| Long Term Debt | $39,438,000,000 | $30,651,000,000 | $25,881,000,000 | $26,886,000,000 |
| Current Debt And Capital Lease Obligation | $8,495,000,000 | $5,983,000,000 | $3,451,000,000 | $12,756,000,000 |
| Current Debt | $8,495,000,000 | $5,983,000,000 | $3,451,000,000 | $12,756,000,000 |
| Other Current Borrowings | $8,495,000,000 | $5,983,000,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $117,666,000,000 | $108,614,000,000 | $98,784,000,000 | $110,574,000,000 |
| Total Non Current Liabilities Net Minority Interest | $63,540,000,000 | $58,293,000,000 | $52,502,000,000 | $54,772,000,000 |
| Other Non Current Liabilities | $9,868,000,000 | $17,549,000,000 | $13,398,000,000 | $10,146,000,000 |
| Tradeand Other Payables Non Current | $486,000,000 | $390,000,000 | $2,881,000,000 | $4,306,000,000 |
| Non Current Deferred Liabilities | $6,791,000,000 | $2,448,000,000 | $3,193,000,000 | $3,991,000,000 |
| Non Current Deferred Taxes Liabilities | $6,791,000,000 | $2,448,000,000 | $3,193,000,000 | $3,991,000,000 |
| Current Liabilities | $54,126,000,000 | $50,321,000,000 | $46,282,000,000 | $55,802,000,000 |
| Payables And Accrued Expenses | $41,097,000,000 | $40,212,000,000 | $38,838,000,000 | $36,407,000,000 |
| Payables | $13,379,000,000 | $14,083,000,000 | $12,625,000,000 | $12,109,000,000 |
| Total Tax Payable | $1,388,000,000 | $3,772,000,000 | $2,993,000,000 | $2,220,000,000 |
| Income Tax Payable | $1,388,000,000 | $3,772,000,000 | $2,993,000,000 | $2,220,000,000 |
| Accounts Payable | $11,991,000,000 | $10,311,000,000 | $9,632,000,000 | $9,889,000,000 |
| Liabilities Heldfor Sale Non Current | - | - | $0 | $2,901,000,000 |
| Other Current Liabilities | - | - | - | $3,590,000,000 |
| Equity | ||||
| Common Stock Equity | $81,544,000,000 | $71,490,000,000 | $68,774,000,000 | $76,804,000,000 |
| Total Equity Gross Minority Interest | $81,544,000,000 | $71,490,000,000 | $68,774,000,000 | $76,804,000,000 |
| Stockholders Equity | $81,544,000,000 | $71,490,000,000 | $68,774,000,000 | $76,804,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-14,930,000,000 | $-11,741,000,000 | $-12,527,000,000 | $-12,967,000,000 |
| Other Equity Adjustments | $-14,930,000,000 | $-11,741,000,000 | $-12,527,000,000 | $-12,967,000,000 |
| Retained Earnings | - | - | $153,843,000,000 | $128,345,000,000 |
| Other | ||||
| Treasury Shares Number | $711,904,000 | $712,921,000 | $712,765,000 | $506,246,000 |
| Ordinary Shares Number | $2,407,939,000 | $2,406,922,000 | $2,407,078,000 | $2,613,597,000 |
| Share Issued | $3,119,843,000 | $3,119,843,000 | $3,119,843,000 | $3,119,843,000 |
| Tangible Book Value | $-17,631,000,000 | $-10,328,000,000 | $-1,959,000,000 | $2,268,000,000 |
| Invested Capital | $129,477,000,000 | $108,124,000,000 | $98,106,000,000 | $116,446,000,000 |
| Working Capital | $1,498,000,000 | $5,572,000,000 | $7,213,000,000 | $-508,000,000 |
| Total Capitalization | $120,982,000,000 | $102,141,000,000 | $94,655,000,000 | $103,690,000,000 |
| Treasury Stock | $75,624,000,000 | $75,680,000,000 | $75,662,000,000 | $41,694,000,000 |
| Additional Paid In Capital | $168,978,000,000 | $155,791,000,000 | $153,843,000,000 | $128,345,000,000 |
| Capital Stock | $3,120,000,000 | $3,120,000,000 | $3,120,000,000 | $3,120,000,000 |
| Common Stock | $3,120,000,000 | $3,120,000,000 | $3,120,000,000 | $3,120,000,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Employee Benefits | $6,957,000,000 | $7,255,000,000 | $7,149,000,000 | $6,542,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,534,000,000 | $4,126,000,000 | $3,993,000,000 | $3,049,000,000 |
| Current Accrued Expenses | $27,718,000,000 | $26,129,000,000 | $26,213,000,000 | $24,298,000,000 |
| Goodwill | $48,772,000,000 | $44,200,000,000 | $36,558,000,000 | $36,047,000,000 |
| Net PPE | $23,169,000,000 | $20,518,000,000 | $19,898,000,000 | $17,982,000,000 |
| Accumulated Depreciation | $-31,195,000,000 | $-28,250,000,000 | $-27,878,000,000 | $-25,552,000,000 |
| Gross PPE | $54,364,000,000 | $48,768,000,000 | $47,776,000,000 | $43,534,000,000 |
| Construction In Progress | $7,361,000,000 | $6,289,000,000 | $5,627,000,000 | $4,677,000,000 |
| Machinery Furniture Equipment | $32,873,000,000 | $29,444,000,000 | $28,979,000,000 | $26,603,000,000 |
| Buildings And Improvements | $13,429,000,000 | $12,317,000,000 | $12,375,000,000 | $11,470,000,000 |
| Land And Improvements | $701,000,000 | $718,000,000 | $795,000,000 | $784,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $7,833,000,000 | $7,292,000,000 | $6,874,000,000 | $6,972,000,000 |
| Work In Process | $3,828,000,000 | $2,815,000,000 | $1,952,000,000 | $1,577,000,000 |
| Raw Materials | $2,530,000,000 | $2,337,000,000 | $2,355,000,000 | $1,719,000,000 |
| Other Short Term Investments | $393,000,000 | $417,000,000 | $1,068,000,000 | $9,392,000,000 |
Fetched: 2026-05-12
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $19,313,000,000 | $18,059,000,000 | $17,778,000,000 | $17,185,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $24,530,000,000 | $24,266,000,000 | $22,791,000,000 | $21,194,000,000 |
| Cash Flow From Continuing Operating Activities | $24,530,000,000 | $24,266,000,000 | $22,791,000,000 | $21,194,000,000 |
| Operating Gains Losses | $-263,000,000 | $-226,000,000 | $-21,101,000,000 | $-380,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-5,217,000,000 | $-6,207,000,000 | $-5,013,000,000 | $-4,009,000,000 |
| Investing Cash Flow | $-23,588,000,000 | $-18,599,000,000 | $878,000,000 | $-12,371,000,000 |
| Cash Flow From Continuing Investing Activities | $-23,588,000,000 | $-18,599,000,000 | $878,000,000 | $-12,371,000,000 |
| Net Other Investing Changes | $-1,571,000,000 | $2,018,000,000 | $-2,593,000,000 | $65,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-5,953,000,000 | $-2,432,000,000 | $-5,054,000,000 | $-6,035,000,000 |
| Issuance Of Capital Stock | $0 | $0 | $4,241,000,000 | $0 |
| Financing Cash Flow | $-5,539,000,000 | $-3,132,000,000 | $-15,825,000,000 | $-8,871,000,000 |
| Cash Flow From Continuing Financing Activities | $-5,539,000,000 | $-3,132,000,000 | $-15,825,000,000 | $-8,871,000,000 |
| Net Other Financing Charges | $-260,000,000 | $234,000,000 | $-1,602,000,000 | $65,000,000 |
| Cash Dividends Paid | $-12,381,000,000 | $-11,823,000,000 | $-11,770,000,000 | $-11,682,000,000 |
| Common Stock Dividend Paid | $-12,381,000,000 | $-11,823,000,000 | $-11,770,000,000 | $-11,682,000,000 |
| Net Common Stock Issuance | $-5,953,000,000 | $-2,432,000,000 | $-813,000,000 | $-6,035,000,000 |
| Common Stock Issuance | $0 | $0 | $4,241,000,000 | $0 |
| Other | ||||
| Repayment Of Debt | $-14,087,000,000 | $-11,886,000,000 | $-24,524,000,000 | $-8,684,000,000 |
| Issuance Of Debt | $23,724,000,000 | $21,937,000,000 | $21,790,000,000 | $16,136,000,000 |
| Interest Paid Supplemental Data | $1,977,000,000 | $1,990,000,000 | $1,836,000,000 | $982,000,000 |
| Income Tax Paid Supplemental Data | $6,539,000,000 | $6,714,000,000 | $8,574,000,000 | $5,223,000,000 |
| End Cash Position | $19,709,000,000 | $24,105,000,000 | $21,859,000,000 | $14,127,000,000 |
| Beginning Cash Position | $24,105,000,000 | $21,859,000,000 | $14,127,000,000 | $14,487,000,000 |
| Effect Of Exchange Rate Changes | $201,000,000 | $-289,000,000 | $-112,000,000 | $-312,000,000 |
| Changes In Cash | $-4,597,000,000 | $2,535,000,000 | $7,844,000,000 | $-48,000,000 |
| Proceeds From Stock Option Exercised | $3,418,000,000 | $838,000,000 | $1,094,000,000 | $1,329,000,000 |
| Common Stock Payments | $-5,953,000,000 | $-2,432,000,000 | $-5,054,000,000 | $-6,035,000,000 |
| Net Issuance Payments Of Debt | $9,637,000,000 | $10,051,000,000 | $-2,734,000,000 | $7,452,000,000 |
| Net Short Term Debt Issuance | $2,256,000,000 | $5,814,000,000 | $-1,183,000,000 | $9,584,000,000 |
| Short Term Debt Payments | $-12,330,000,000 | $-9,463,000,000 | $-22,973,000,000 | $-6,550,000,000 |
| Short Term Debt Issuance | $14,586,000,000 | $15,277,000,000 | $21,790,000,000 | $16,134,000,000 |
| Net Long Term Debt Issuance | $7,381,000,000 | $4,237,000,000 | $-1,551,000,000 | $-2,132,000,000 |
| Long Term Debt Payments | $-1,757,000,000 | $-2,423,000,000 | $-1,551,000,000 | $-2,134,000,000 |
| Long Term Debt Issuance | $9,138,000,000 | $6,660,000,000 | $0 | $2,000,000 |
| Net Investment Purchase And Sale | $741,000,000 | $736,000,000 | $8,484,000,000 | $9,225,000,000 |
| Sale Of Investment | $1,661,000,000 | $2,462,000,000 | $19,390,000,000 | $41,609,000,000 |
| Purchase Of Investment | $-920,000,000 | $-1,726,000,000 | $-10,906,000,000 | $-32,384,000,000 |
| Net Business Purchase And Sale | $-17,541,000,000 | $-15,146,000,000 | $0 | $-17,652,000,000 |
| Purchase Of Business | $-17,541,000,000 | $-15,146,000,000 | $0 | $-17,652,000,000 |
| Net Intangibles Purchase And Sale | $-385,000,000 | $-1,783,000,000 | $-470,000,000 | $0 |
| Purchase Of Intangibles | $-385,000,000 | $-1,783,000,000 | $-470,000,000 | $0 |
| Net PPE Purchase And Sale | $-4,832,000,000 | $-4,424,000,000 | $-4,543,000,000 | $-4,009,000,000 |
| Purchase Of PPE | $-4,832,000,000 | $-4,424,000,000 | $-4,543,000,000 | $-4,009,000,000 |
| Change In Working Capital | $-12,718,000,000 | $1,837,000,000 | $2,507,000,000 | $-4,011,000,000 |
| Change In Other Current Liabilities | $-5,697,000,000 | $33,000,000 | $5,588,000,000 | $-1,979,000,000 |
| Change In Other Current Assets | $-6,167,000,000 | $1,717,000,000 | $-3,480,000,000 | $687,000,000 |
| Change In Payables And Accrued Expense | $2,377,000,000 | $1,621,000,000 | $2,346,000,000 | $1,098,000,000 |
| Change In Inventory | $-1,450,000,000 | $-1,128,000,000 | $-1,323,000,000 | $-2,527,000,000 |
| Change In Receivables | $-1,781,000,000 | $-406,000,000 | $-624,000,000 | $-1,290,000,000 |
| Changes In Account Receivables | $-1,781,000,000 | $-406,000,000 | $-624,000,000 | $-1,290,000,000 |
| Other Non Cash Items | $109,000,000 | $1,841,000,000 | $483,000,000 | - |
| Stock Based Compensation | $1,354,000,000 | $1,176,000,000 | $1,162,000,000 | $1,138,000,000 |
| Provisionand Write Offof Assets | $-1,000,000 | $11,000,000 | $0 | $-17,000,000 |
| Asset Impairment Charge | $204,000,000 | $405,000,000 | $1,295,000,000 | $1,216,000,000 |
| Deferred Tax | $1,538,000,000 | $-2,183,000,000 | $-4,194,000,000 | $-1,663,000,000 |
| Deferred Income Tax | $1,538,000,000 | $-2,183,000,000 | $-4,194,000,000 | $-1,663,000,000 |
| Depreciation Amortization Depletion | $7,503,000,000 | $7,339,000,000 | $7,486,000,000 | $6,970,000,000 |
| Depreciation And Amortization | $7,503,000,000 | $7,339,000,000 | $7,486,000,000 | $6,970,000,000 |
| Gain Loss On Sale Of Business | $-263,000,000 | $-226,000,000 | $-21,101,000,000 | $-380,000,000 |
| Net Income From Continuing Operations | $26,804,000,000 | $14,066,000,000 | $35,153,000,000 | $17,941,000,000 |
Fetched: 2026-05-12